



IMPACT

Incidental Meningioma: Prognostic Analysis Using Patient Comorbidity and MRI-Tests

External validation and calibration of an incidental meningioma prognostic model – IMPACT: protocol for an international multicentre retrospective cohort study

Study sponsor	University of Liverpool Crown Street Liverpool L69 3BX United Kingdom
Trainee leads	Abdurrahman I Islim Christopher P Millward
Chief investigator	Michael D Jenkinson
Version number and date	Version 5.3, 3 rd July 2020



Steering committee	
<p>Abdurrahman I. Islim Academic Foundation Doctor University of Liverpool & Royal Liverpool University Hospital, Liverpool, UK</p>	<p>Christopher P. Millward Specialist Trainee in Neurosurgery & PhD candidate University of Liverpool & The Walton Centre NHS Foundation Trust, Liverpool, UK</p>
<p>Michael D. Jenkinson Professor of Neurosurgery & Hon. Consultant Neurosurgeon University of Liverpool & The Walton Centre NHS Foundation Trust, Liverpool, UK</p>	<p>Thomas Santarius Consultant Neurosurgeon Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK</p>
<p>Ryan K. Mathew Associate Professor & Hon. Consultant Neurosurgeon University of Leeds, Leeds, UK</p>	<p>Andrew R. Brodbelt Consultant Neurosurgeon The Walton Centre NHS Foundation Trust, Liverpool, UK</p>
<p>Samantha J. Mills Consultant Neuroradiologist The Walton Centre NHS Foundation Trust, Liverpool, UK</p>	<p>Ruwanthi Kolamunnage-Dona Professor of Medical Statistics University of Liverpool, Liverpool, UK</p>
<p>Shaveta Mehta Consultant Clinical Oncologist The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK</p>	<p>Rory Piper NIHR academic clinical fellow & specialist Trainee in Neurosurgery University of Oxford, Oxford, UK</p>

STUDY SYNOPSIS

Short title External Validation of IMPACT

Study ID IMPACT

Study description An international multi-centre retrospective study of incidental meningioma to externally validate and calibrate a prognostic model of radiological and clinical progression – IMPACT (*Incidental Meningioma: Prognostic Analysis Using Patient Comorbidity and MRI Tests*).

Primary objective To externally validate the prognostic model IMPACT, i.e. to determine if IMPACT can accurately predict the clinical and radiological outcome of an incidental asymptomatic intracranial meningioma.


Secondary objectives

- To calibrate the prognostic model IMPACT
- Determine the growth patterns of incidental meningiomas
- Determine the imaging and histopathological characteristics of tumours subject to surgical resection
- Determine the risk of post-intervention complications and tumour recurrence/growth for meningiomas subject to surgery, stereotactic radiosurgery or radiotherapy.
- Assess the economic implications of stratifying follow-up according to risk of disease progression.

Study design Retrospective study of longitudinal radiological and clinical outcomes of incidental intracranial meningioma patients at participating centres diagnosed between 01/01/2009 and 31/12/2010. Data will be recorded until death or last date of follow-up.

Sample size 1500 patients

STUDY FLOWCHART



CONTENTS

1	INTRODUCTION	6
2	OBJECTIVES	7
2.1.	Primary objective	7
3	METHODS	7
3.1.	Study design	7
3.2.	Study population and eligibility criteria	7
3.3.	Sample size	8
3.4.	Study endpoints	9
3.4.1.	<i>Primary endpoint</i>	9
3.4.2.	<i>Secondary endpoints</i>	9
3.5.	Data collection and recorded variables	9
3.5.1.	<i>Baseline clinical variables</i>	10
3.5.2.	<i>Baseline radiological variables</i>	11
3.5.3.	<i>Management strategy</i>	12
3.5.4.	<i>Overall outcomes</i>	13
3.6.	Quality assurance	13
3.7.	Planned statistical analysis	14
3.7.1.	<i>External validation</i>	14
3.7.2.	<i>Additional analyses</i>	15
4	ETHICS AND GOOD CLINICAL PRACTICE	15
4.1.	Study registration	15
4.2.	Local investigator responsibilities	15
4.3.	Confidentiality and data protection	15
5	PUBLICATION AND PRESENTATION OF DATA	16
5.1.	Ownership	16
5.2.	Dissemination of results	16
5.3.	Authorship eligibility	16
6	FUNDING	16
7	STUDY TIMELINE	17
8	CONCLUSION	17
9	REFERENCES	17
10	APPENDICES	19
10.1.	Appendix. 1	19
10.2.	Appendix. 2	36

1 INTRODUCTION

Meningiomas have the highest incidence rate amongst all primary central nervous system (CNS) tumours. Descriptive studies from Europe and North America suggest this rate to be between 4.20 and 8.58 per 100,000 individuals (1, 2). Wider access and increased use of MRI and CT has led to a marked rise in the number of incidental findings in clinical and research settings, with meningiomas comprising a sizeable proportion (3). A recent study of the SEER database demonstrated a significant increase in early detection of smaller, incidental tumours; between 2004 and 2012, the proportion of <1 cm meningiomas diagnosed in a given year increased in a linear fashion from six to 11% (4). Incidental, asymptomatic meningiomas cause patient anxiety and uncertainty around the need for future treatment and often prompt clinicians to commence long-term MRI and clinical follow-up. International consensus guidelines by the European Association of Neuro-Oncology (EANO) and National Comprehensive Cancer Network (NCCN) suggest active monitoring with MRI as first line for managing these tumours (5, 6), however, data to advise on the optimal follow-up duration and screening intervals are lacking (7).

Previous studies have identified prognostic radiological factors that are associated with the risk of meningioma growth and development of clinical symptoms; however, the timing of such progression is poorly defined (8-10). Moreover, clinical factors such as patient comorbidity and performance status remain unexplored in relation to prognosis but are highly relevant. The patient with an incidental meningioma wants to know whether their tumour will grow and become symptomatic such that it will require safe treatment within their healthy lifetime.

To this end, we recently completed a retrospective cohort study of incidental meningioma patients at the Walton Centre NHS Foundation Trust, Liverpool, UK with the aim of assessing the utility of combining routinely available radiological and clinical factors to develop a prognostic model for the risk of incidental meningioma progression during active monitoring (11). The resulting model IMPACT (*I*ncidental *M*eningioma: *P*rognostic *A*nalysis Using Patient *C*omorbidity and MRI *T*ests) could be used as a tool to guide active monitoring strategies for patients with an incidental asymptomatic meningioma within the first 10 years of diagnosis, however validation with external datasets is required.

This international retrospective cohort study of incidental meningioma has the primary aim of externally validating and calibrating of the prognostic model IMPACT, accessible using <https://www.impact-meningioma.com>. These data will provide insight into the incidence, epidemiology, presentation, management, and long-term outcomes of incidental meningioma, which will inform the development of clinical guidelines and identify areas for future research.

2 OBJECTIVES

2.1. Primary objective

To externally validate the prognostic model IMPACT.

2.2. Secondary objectives

- A. To calibrate the prognostic model IMPACT
- B. Determine the growth patterns of incidental meningiomas
- C. Determine the imaging and histopathological characteristics of tumours subject to surgical resection
- D. Determine the risk of post-intervention complications and tumour recurrence/growth for meningiomas subject to surgery, stereotactic radiosurgery or radiotherapy
- E. Assess the economic implications of stratifying follow-up according to risk of disease progression

3 METHODS

3.1. Study design

This is a retrospective, international multicentre cohort study. The study will include incidental meningioma patients managed at each participating centre. Cases will be identified by the local site research team using existing patient medical records. Baseline clinical and radiological characteristics, tumour management and clinical and radiological outcomes will be collected and recorded (anonymised data) on a secure database by the local investigator. Since this study falls within the remit of clinical outcomes audit, patient consent will not be sought for the use of their data. The study will recruit patients managed over a 2-year period between 1st January 2009 and 31st December 2010. This is an observational study and will not impact on routine patient care.

3.2. Study population and eligibility criteria

Adults (≥ 16 years of age) with a newly identified incidental meningioma, as per radiology report, diagnosed between 1st January 2009 and 31st December 2010. Radiological diagnosis is expected to be based on the presence of an extra-axial lesion with broad-based attachment along the dura showing contrast enhancement. The adopted definition of an incidental finding is “a previously undetected abnormality of potential clinical relevance that is unexpectedly discovered and unrelated to the purpose of the examination”.

Exclusion criteria are as follows:

- A. History of cranial radiation >5 years from diagnosis
- B. History of neurofibromatosis type 2
- C. Surgical resection which revealed a different histopathological diagnosis
- D. Unavailability of medical notes including radiological images

3.3. Patient identification

Eligible patients can be identified using local radiology information systems, e.g. the Computerised Radiological Information System (CRIS) tool. The search term will be as follows: “incidental” OR “asymptomatic” OR “small” AND “meningioma” (Figure 1). The process of patient identification will be piloted prior to data collection. Personalised search strategies will be assigned to centres with less than expected yield (<20-40 patients/year depending on the population size) following deliberation with the local study team.




Figure 1. Process of creating a provisional patient list at each study

3.4. Sample size

For external validation studies, a minimum of 100 events, is required (12). The IMPACT study based in the Walton Centre NHS Foundation Trust (2007-2015) included 441 (459 meningiomas) patients and 44 progressed (~10%). We aim to include a minimum of 1500 patients across participating centres.

3.5. Study endpoints

3.5.1. Primary endpoint

Disease progression will be defined using a composite endpoint comprising of new symptom development, meningioma-specific mortality, meningioma growth (absolute growth rate ≥ 2 cm³/year or absolute growth rate ≥ 1 cm³/year + relative growth rate $\geq 30\%$ /year), development or increase of peritumoural brain oedema (defined as increased signal intensity on T2), venous sinus invasion and meningioma volume exceeding 10 cm³. The first two criteria denote clinical progression while the latter three are related to loss of window of curability. Venous sinus invasion and peritumoural oedema can prevent complete surgical resection (13, 14). Peritumoural oedema and a meningioma volume >10 cm³ are relative contraindications to stereotactic radiosurgery (15, 16).

3.5.2. Secondary endpoints

Intervention (surgery, stereotactic radiosurgery or radiotherapy) and mortality unrelated to the meningioma.

3.6. Data collection

Data will be collected at each centre by a member of the local team. Data will be collected from the patient's case records and MRI images. All clinical and radiological information collected for this study by the local investigators should be available routinely and no extra patient assessment will be required. Data will be collected and stored online through a secure server running the Research Electronic Data Capture (REDCap) web application and using the patient unique study number. Local investigators will be given secure REDCap project server login details (one login per site). No patient identifiable information will be uploaded or stored on the REDCap database. The study number (site ID_patient ID) is generated by REDCap on creating a new patient record in the database. The clinical team can only view the records of patients from their own centre. All local investigators will store a copy of the link between the patient's unique study number and their patient identifiers on a secure password protected NHS computer, using a blank link file provided by the study team.

3.7. REDCap database

Access to REDCap will be provided by the Liverpool Clinical Trials Centre (LCTC), University of Liverpool, a partner of the REDCap consortium. Database programmers will oversee the development of a data collection tool which can be accessed using any electronic device with internet access. Quality assessment of the tool will be done over two phases. Phase 1 will involve local testing of the tool using pre-existing data (Liverpool cohort). Five cases with

variable outcomes will be picked to ensure all possible variables are tested. Phase 2 will expand testing to three more centres (Cambridge, Leeds and Manchester; subject to approval), using a similar number of cases. After completion of phase 2, the data collection tool will be made live for use by the participating sites.

3.8. Recorded variables

3.8.1. **Baseline clinical variables**

Age at diagnosis, sex, ethnicity, the World Health Organisation (WHO) performance status (PS) (Table 1) and the age adjusted Charlson comorbidity index (ACCI) (Table 2). An ACCI calculator (appendix 2) will be made available for use via a Microsoft Excel worksheet. These factors will only be recorded at baseline.

Table 1. WHO performance status classification		Table 2. Age-adjusted Charlson comorbidity index		
Score	Description	Condition		weight
0	able to carry out all normal activity without restriction	Age (years)	<50	0
1	Restricted in strenuous activity but ambulatory and able to carry out light work		50-59	1
2	Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours		60-69	2
3	Symptomatic and in a chair or in bed for greater than 50% of the day but not bedridden		70-79	3
4	Completely disabled; cannot carry out any self-care; totally confined to bed or chair.		≥80	4
5	Dead	Myocardial infarction		1
		Congestive heart failure		1
		Peripheral vascular disease		1
		Hemiplegia		2
		Cerebrovascular disease		1
		Pulmonary disease		1
		Diabetes		1
			With end organ damage	2
		Renal disease		2
		Liver disease	Mild	1
			Severe	3
		Peptic ulcer disease		1
		Cancer		2
			Metastatic	6
		Dementia		1
		Connective tissue disease		1

	AIDS		6
	Hypertension		1
	Skin ulcers/cellulitis		2
	Depression		1
	On Warfarin		1

3.8.2. Baseline radiological variables

A video and a manual prepared by the study team will be made available to assist with standardisation of image interpretation across participating centres.

Baseline imaging variables assessed will be:

- I. Single or multiple meningioma
- II. Tumour signal intensity compared to the contralateral grey matter on fluid attenuated inversion recovery (FLAIR) and T2-weighted (T2) MRI (hypo/iso/hyper).
- III. Peritumoural signal intensity in relation to tumour volume using the signal change present on FLAIR and T2 MRI (0-5%/6-33%/34-66%/67-100%; adapted from the VASARI [Visually Accessible Rembrandt Images] MR features for gliomas (17)).
- IV. Meningioma volume using the ABC/2 formula on contrast-enhanced T1-weighted MRI/CT: (A) maximum meningioma diameter on axial plane, (B) diameter perpendicular to (A) and (C) maximum height on coronal/sagittal plane, not taking into the account the dural tail.
- V. Meningioma location classed into non-skull base and skull base and further subcategorised according to the ICOM (International Consortium on Meningioma) classification system (Appendix 2).
- VI. Proximity to major dural venous sinuses (superior sagittal sinus/transverse sinus/sigmoid sinus/cavernous sinus/the confluence of sinuses) categorised as separate (within 10 mm), in direct contact with its wall or invading, excluding the dural tail.
- VII. Contact with critical neuro-vascular structures (i.e. internal carotid artery and optic apparatus).

Meningiomas that fulfil one of the two previous categories (VII or VIII) are said to be in proximity to critical neurovascular structures.




Fig. 2. (A-C) T2 MR axial sequences showing the 3 levels of tumour intensity (circle). (A) Hypointense. (B) Isointense. (C) Hyperintense. (D-F) T1-weighted MR with gadolinium (contrast) showing the relationship between the meningioma and the nearby venous sinus (SSS). (D) Separate as there's no clear attachment to the sinus wall. (E) In direct contact with the lateral wall of the sinus. (F) Clear macroscopic distortion and invasion of the sinus. The labelling has gone a bit wrong

3.8.3. Management strategy

Management strategies will be dichotomised either to active monitoring or intervention (surgery, stereotactic radiosurgery (SRS), fractionated radiotherapy (fRT) and discharge from outpatient clinic care). **Active monitoring** is defined as regular surveillance imaging and outpatient clinical observation. Recorded factors will include:

- I. Number of scans, and interval between them (months).
- II. For each scan: peritumoural signal intensity, venous sinus involvement and meningioma volume.
- III. Each scan will be examined alongside its corresponding outpatient clinic appointment for any evidence of meningioma-related symptoms (motor/sensory/language/cognitive/seizure/headache/other).
- IV. The outcome of each clinical encounter (i.e. outpatient appointment) will be recorded (resume follow-up/surgery/SRS/fRT/hospital discharge).

Intervention details if performed will be also recorded. These will include indication for intervention (clinical-radiological/clinical/radiological/patient preference) and time to intervention. For patients treated with clinical-radiological or clinical progression, status of meningioma-related neurological morbidity will be noted.

For surgery the following will additionally be recorded:

- I. Simpson score (as recorded by the surgeon in the operative notes).
- II. WHO grade (classified according to the WHO system in use at the time of surgery and updated according to the WHO 2016 classification dependent on pathologists' availability (18)) and presence of any reported brain invasion (yes / no / not reported).
- III. Postoperative medical and surgical complications recorded at 30 days (Landriel-Ibañez Classification (Table 3) (19)).
- IV. Follow-up duration (months).
- V. WHO performance status pre- and postoperatively and at the last follow-up appointment.
- VI. Recurrence on contrast-enhanced MRI during that time (yes/no) and if recurred then the time to recurrence.

For SRS and fRT:

- I. Fractionated dose (fRT), number of fractions (fRT) and total dose (fRT /SRS).
- II. Early and late (≥ 3 months) toxicity (assessed by CTCAE v5.0, https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm).
- III. Duration of follow-up post-radiation (months).
- IV. WHO performance status pre- and post-radiation and at the last follow-up appointment.
- V. Tumour size on last available imaging.

For patients discharged from outpatient care data sources will be checked for any readmissions/rescans thought to be attributed to the incidental meningioma within the study timeframe. Outcome following readmissions/rescans will be noted.

Table 3. Landriuel-Ibañez classification of neurosurgical complications	
Grade I	Any non–life-threatening deviation from normal postoperative course, not requiring invasive treatment
Grade Ia	Complication requiring no drug treatment
Grade Ib	Complication requiring drug treatment
Grade II	Complication requiring invasive treatment such as surgical, endoscopic, or endovascular interventions
Grade IIa	Complication requiring intervention without general anaesthesia
Grade IIb	Complication requiring intervention with general anaesthesia
Grade III	Life-threatening complications requiring management in ICU
Grade IIIa	Complication involving single organ failure
Grade IIIb	Complication involving multiple organ failure
Grade IV	Complication resulting in death
Surgical Complications	Adverse events that are directly related to surgery or surgical technique
Medical Complications	Adverse events that are not directly related to surgery or surgical technique
Suffix “T” (Transient)	New neurologic deficit improving within 30 days of surgical procedure; can be added to each grade of complication
Suffix “P” (Persistent)	New neurologic deficit extending beyond 30 days of surgical procedure; can be added to each grade of complication

3.8.4. Overall outcomes

Overall outcomes by the end of the study period (discharge from outpatient care/lost to follow-up/dead/under on-going active follow-up) and follow-up durations will be recorded. Any deaths encountered during follow-up will be recorded. The medical records for patients discharged will also be examined for mortality data.

3.9. Quality assurance

For each participating centre, a quality assurance process will take place. Local investigators will be required to upload their extracted data alongside the MRI scans for the first 5 cases. Central review of imaging and clinical data by the study team will be performed. Once approved with no discrepancies, the remainder of the data may be uploaded. Identified issues will be discussed before a consensus is reached. Recurring issues across participating centres will be addressed using web-based information videos and webinars.

3.10. Planned statistical analysis

3.10.1. External validation

Using IMPACT, we will calculate the 5- and 10-year estimated risk of disease progression for every patient included in this cohort study. Kaplan-Meier method will be used to obtain the observed risks. The predictive performance of IMPACT will be assessed by examining measures of calibration and discrimination. Calibration refers to how closely the predicted 5- and 10-year risk of progression agrees with the observed risk. A calibration plot compares the observed and predicted rates of events for each group. A perfect match indicates accurate calibration. The Brier score for censored survival data will also be calculated, which is a measure of accuracy and is the average squared deviation between predicted and observed risk; a lower score represents greater accuracy. Discrimination is the ability of the risk score to differentiate between those patients who do and those who do not experience disease progression during the study timeframe. This measure is quantified by calculating the C-statistic, D-statistic and Chambless and Diao's time-dependent AUC (area under the receiver operating characteristic curve [ROC]) which are tailored towards censored survival data. Model assumptions will be tested by examination of Schoenfeld residuals, and influential observations will be examined using DFBETA panels.

The effect of patient age, comorbidity and performance status on the risk of disease progression and intervention will be assessed using a competing risk analysis. Patients will be split based on WHO PS into two categories: 0-1 and 2-4 and stratified by ACCI into three groups: 0-2, 3-5 and ≥ 6 . An ACCI score of ≤ 2 corresponds to patients who are young (<60 years) with few or no comorbidities. An ACCI score of 3–5 corresponds to either an older patient with few comorbidities, or a younger patient with several comorbidities, and an ACCI score ≥ 6 denotes older patient with comorbidities (20).

Two competing risk analyses will be performed. One assessing the cumulative incidence rate (CIR) of primary intervention at different time points following diagnosis stratified by PS and ACCI groups and the other will evaluate the CIR of disease progression. The competing event for the former will be non-meningioma-specific mortality either observed during follow-up or after being discharged from outpatient care. Patients who remain under follow-up will be censored at the last outpatient clinic appointment. Patients discharged alive from outpatient care will be censored at last time they were seen by a healthcare physician i.e. general practitioner.

For the disease progression analysis, mortality after hospital discharge could not be used as a competing event as the time interval between discharge and death could have witnessed radiological changes which meet the disease progression definition. Instead, four events will be considered competing in nature, discharge from outpatient care, loss to follow-up, death during follow-up or an intervention before disease progression occurred with the first three grouped together. Censoring will only be done for patients who remain under follow-up at the last clinic appointment. To test the equality across CIR groups, the Fine and Gray test will

be carried out. Plots of CIRs and 95% confidence intervals (CIs) will also be generated and compared to the training data set (Walton Centre).

3.10.2. Additional analyses

We envisage that imaging protocols in the participating centres are varied and non-standardised and thus, the growth rate for each meningioma will be determined using a joint longitudinal and event-time outcomes model which does not require regularly spaced time points, and adjusts for informative follow-up, assuming a different intercept and slope for each meningioma (21, 22). The sum of the regression coefficients of random and fixed effects for the slope estimated from the linear model will best represent the average growth rate for each meningioma. Absolute growth rate (AGR) will be defined as the increase in volume per year in cm³ whereas relative growth rate (RGR) will be defined as the percentage increase in volume per year.

Demographic differences across management and outcome groups will be explored with the χ^2 test for categorical variable and the Mann-Whitney U test or Student's t-test for continuous variables. Correlation between baseline variables will be evaluated using the Pearson correlation coefficient. Normally distributed continuous variables will be expressed as mean (standard deviation [SD]) whereas skewed variables as median (interquartile range [IQR]). Differences will be considered statistically significant at $P < 0.05$.

This statistical analysis plan will be reviewed prior to the final analysis of the study.

4 ETHICS AND GOOD CLINICAL PRACTICE

4.1. Study registration

It is the responsibility of the research team at each unit to register the study as a clinical audit with their hospital's audit department, including Caldicott guardian approval as required.

4.2. Local investigator responsibilities

The investigator is responsible for the overall conduct of the study at the site and compliance with the protocol. Responsibilities may be delegated to an appropriate member of the local research team. The Investigator must also be familiar with the protocol and the study requirements and it is their responsibility to ensure that all staff assisting with the study are adequately informed about the protocol and the study requirement. The Principal Investigator at each centre is responsible for the quality of the data recorded in the database.

4.3. Confidentiality and data protection

All records must be identified in a manner designed to maintain patient confidentiality and must be kept in a secure storage area with limited access. The investigator and local research terms involved with this study may not disclose or use for any purpose other than performance of the study, any data, record, or other unpublished, confidential information.

They also must comply with the requirements of the Data Protection Act 1998 with regard to the collection, storage, processing and disclosure of personal information and will uphold the Act's core principles. Access to collated patient data will be restricted to individuals from the research team and representatives of the sponsor. Computers used to collate the data will have limited access measures via usernames and passwords. Published results will not contain any personal data that could allow identification of individual patients.

5 PUBLICATION AND PRESENTATION OF DATA

5.1. Ownership

Ownership of the complete dataset arising from this study resides with the research team (details on page 2 of the protocol). Local data collected as part of this study belongs to the local team collecting that data. However, individual clinicians must not submit any part of their individual data for publication or presentation without prior consent from the study research team.

5.2. Dissemination of results

The study results will be reported using the TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis) checklist. The results of this study will be presented at national and international meetings and will be submitted for publication in peer-reviewed journals.

5.3. Authorship eligibility

Fully named authors must satisfy the ICMJE (International Committee of Medical Journal Editors) conditions for authorship. Each contributing centre can provide up to 2 fully named authors. The contribution of all other participants will be recognised with PubMed Citable collaborator-status authorship under the umbrella of the British Neurosurgical Trainee Research Collaborative (BNTRC). Further collaborator-status authorship will be provided to non-UK contributors under the umbrella of the International Consortium on Meningioma (ICOM).

6 FUNDING

No funding has been sought for the completion of this project. Certain elements of this study will be covered by funding received by the Chief Investigator (MDJ) from The Brain Tumour Charity.

7 STUDY TIMELINE

Activity	Up to Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan-21	Feb-21 - Jul-21	Aug-21 - Oct-21	Nov-21	Dec-21
Arrange REDCap access	Completed										
Build REDCap database, phase 1	Completed										
Build REDCap database, phase 2		On hold									
Recruit centres	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing				
Local audit approval	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing				
Identification of patients	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing				
Data collection	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing	Ongoing				
Data processing and analysis									On hold		
Results presentation										On hold	
Publication of report											On hold
	Completed										
	Ongoing										
	On hold										

8 CONCLUSION

This study will be the first international multicentre study collecting data on outcomes of management of incidental asymptomatic meningioma which will enable validation of the IMPACT prognostic model and from the basis of ongoing prospective and economic studies.

9 REFERENCES

1. Cea-Soriano L, Wallander MA, Garcia Rodriguez LA. Epidemiology of meningioma in the United Kingdom. *Neuroepidemiology*. 2012;39(1):27-34.
2. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. *Neuro Oncol*. 2019;21(Supplement_5):v1-v100.
3. Morris Z, Whiteley WN, Longstreth Jr WT, Weber F, Lee YC, Tsushima Y, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ (Clinical research ed)*. 2009;339:b3016.
4. Agarwal V, McCutcheon BA, Hughes JD, Carlson ML, Glasgow AE, Habermann EB, et al. Trends in Management of Intracranial Meningiomas: Analysis of 49,921 Cases from Modern Cohort. *World Neurosurg*. 2017;106:145-51.
5. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. *The Lancet Oncology*. 2016;17(9):e383-91.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Central Nervous System Cancer (Version 1.2017) [cited 2017 November 11]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
7. Islim AI, Mohan M, Moon RDC, Srikantharajah N, Mills SJ, Brodbelt AR, et al. Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. *J Neurooncol*. 2019;142(2):211-21.

8. Romani R, Ryan G, Benner C, Pollock J. Non-operative meningiomas: long-term follow-up of 136 patients. *Acta Neurochir (Wien)*. 2018.
9. Zeng L, Liang P, Jiao J, Chen J, Lei T. Will an Asymptomatic Meningioma Grow or Not Grow? A Meta-analysis. *Journal of neurological surgery Part A, Central European neurosurgery*. 2015;76(5):341-7.
10. Behbahani M, Skeie GO, Eide GE, Hausken A, Lund-Johansen M, Skeie BS. A prospective study of the natural history of incidental meningioma—Hold your horses! *Neuro-Oncology Practice*. 2019;6(6):438-50.
11. Islim AI, Kolamunnage-Dona R, Mohan M, Moon RDC, Crofton A, Haylock BJ, et al. A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas. *Neuro Oncol*. 2019;22(2):278-89.
12. Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA: a cancer journal for clinicians*. 2016;66(5):370-4.
13. Vignes JR, Sesay M, Rezajooi K, Gimbert E, Liguoro D. Peritumoral edema and prognosis in intracranial meningioma surgery. *J Clin Neurosci*. 2008;15(7):764-8.
14. Han MS, Kim YJ, Moon KS, Lee KH, Yang JI, Kang WD, et al. Lessons from surgical outcome for intracranial meningioma involving major venous sinus. *Medicine*. 2016;95(35).
15. Cai R, Barnett GH, Novak E, Chao ST, Suh JH. Principal risk of peritumoral edema after stereotactic radiosurgery for intracranial meningioma is tumor-brain contact interface area. *Neurosurgery*. 2010;66(3):513-22.
16. Kollova A, Liscak R, Novotny J, Jr., Vladyka V, Simonova G, Janouskova L. Gamma Knife surgery for benign meningioma. *J Neurosurg*. 2007;107(2):325-36.
17. The Cancer Imaging Archive. Wiki for the VASARI feature set. The National Cancer Institute Web site, <https://wiki.cancerimagingarchive.net/display/Public/VASARI+Research+Project>. (2015) (Date of access: 06/01/2018).
18. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta neuropathologica*. 2016;131(6):803-20.
19. Landriel Ibanez FA, Hem S, Ajler P, Vecchi E, Ciraolo C, Baccanelli M, et al. A new classification of complications in neurosurgery. *World Neurosurg*. 2011;75(5-6):709-15; discussion 604-11.
20. Koppie TM, Serio AM, Vickers AJ, Vora K, Dalbagni G, Donat SM, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. *Cancer*. 2008;112(11):2384-92.
21. Kolamunnage-Dona R, Williamson PR. Time-dependent efficacy of longitudinal biomarker for clinical endpoint. *Statistical Methods in Medical Research*. 2016;27(6):1909-24.
22. Williamson PR, Kolamunnage-Dona R, Philipson P, Marson AG. Joint modelling of longitudinal and competing risks data. *Statistics in medicine*. 2008;27(30):6426-38.

10 APPENDICES

10.1. Appendix. 1. Guide for REDCap database developers

Characteristic	Options	Notes
BASELINE CLINICAL CHARACTERISTICS (PAGE/SECTION 1)		
Age (years)	Free field	Required entry
Sex	Dropdown list/check box <ul style="list-style-type: none"> • Male • Female 	
Ethnicity	Dropdown list/check box <ul style="list-style-type: none"> • White • Mixed / Multiple ethnic groups • Asian / Asian British • Black / African / Caribbean / Black British • Other ethnic group • NA 	Required entry. Allow one option only. Other ethic group prompts a free text box
Comorbidities	Check box <ul style="list-style-type: none"> • Hypertension - systolic > 140 or diastolic > 90 and patients on medical treatment • Previous myocardial infarction • Congestive heart failure • Peripheral vascular disease • Previous stroke/TIA - If hemiplegia present, do not check • Hemi/paraplegia • Diabetes which requires medical treatment 	Required entry. Allow multiple options. Note to data collector: Age and comorbidities will be used to calculate the age adjusted Charlson comorbidity index. Each of these is defined in the guide provided

	<ul style="list-style-type: none"> • Diabetes with end-organ damage - if so, do not check diabetes that requires treatment • COPD/Asthma • Renal disease • Mild liver disease - Hep B/C or cirrhosis without portal hypertension • Moderate to severe liver disease - cirrhosis with portal hypertension, jaundice, ascites • Peptic ulcer disease • Cancer - excluding basal cell carcinoma • Metastatic cancer - if so, do not check cancer • Rheumatic or connective tissue disease • HIV/AIDS • Skin ulcers/cellulitis • Depression • Dementia • On Warfarin 	
WHO Performance status	Dropdown list/check box <ul style="list-style-type: none"> • 0 • 1 • 2 • 3 • 4 	Required entry. Allow one option only
Indication for scan	Dropdown list/check box <ul style="list-style-type: none"> • Headache • Cerebrovascular accident • Head injury • Audiovestibular symptoms 	Required entry. Allow multiple options. Note to data collector: The meningioma must not be thought to be the cause of these symptoms. Other indications might include lethargy, research, sinusitis, anosmia...etc. Other prompts a free text box

	<ul style="list-style-type: none"> • Visual symptoms • Psychiatric symptoms • Cognitive symptoms • Loss of consciousness • Other 	
NUMBER OF MENINGIOMAS ON 1ST DIAGNOSTIC SCAN (PAGE/SECTION 2)		
Initial scan date	DD/MM/YYYY	Required entry. YYYY can't be ≤2007 or ≥2011
How many meningiomas?	Check box <ul style="list-style-type: none"> • Single • Multiple 	Required entry If a single meningioma, direct to section/page 3. If multiple, prompt a new entry point (e.g. check box with options being 2-6) with number of meningiomas present. Each meningioma will then be treated as a separate entity with regards to the upcoming sections.
BASELINE IMAGING CHARACTERISTICS (SECTION/PAGE 3)		
Meningioma signal intensity on T2	Dropdown list/check box <ul style="list-style-type: none"> • Hypointense • Hyperintense • Isointense • NA 	Required entry. Allow one option only Note to data collector: In relation to the contralateral grey matter. If only baseline CT available, NA
Meningioma signal intensity on FLAIR	Dropdown list/check box <ul style="list-style-type: none"> • Hypointense • Hyperintense • Isointense • NA 	Required entry. Allow one option only Note to data collector: In relation to the contralateral grey matter. If only baseline CT available, NA
Peritumoural signal intensity on T2	Dropdown list/check box <ul style="list-style-type: none"> • 0-5% • 6-33% • 34-66% • 67-100% • NA 	Required entry. Allow one option only Note to data collector: In relation to tumour volume. If only baseline CT available, NA
Peritumoural signal intensity on FLAIR	Dropdown list: <ul style="list-style-type: none"> • 0-5% • 6-33% • 34-66% • 67-100% • NA 	Required entry. Allow one option only Note to data collector: In relation to tumour volume. If only baseline CT available, NA
Venous sinus nearby	Checkbox	Required entry.

		Note to data collector: Tick box if within 10 mm, in direct contact or invading one of: superior sagittal sinus (SSS), sigmoid sinus (SS), transverse sinus (TS), cavernous sinus (CS) and the confluence of sinuses (CoS)
If yes, specify	Dropdown list/check box <ul style="list-style-type: none"> • Superior sagittal sinus • Cavernous sinus • Sigmoid sinus • Transverse sinus • Confluence of sinuses 	Prompt entry if previous option (venous sinus nearby) has been ticked. Allow one option only.
Separate, direct contact or invaded?	Dropdown list/check box <ul style="list-style-type: none"> • Separate • Direct contact • Invaded 	Prompt entry if previous option (venous sinus nearby) has been ticked. Allow one option only
In contact with critical neuro-vascular structures?	Checkbox	Required entry
If yes, which	Dropdown list/check box <ul style="list-style-type: none"> • Internal carotid artery • Basilar artery • Vertebral artery • Middle cerebral artery • Anterior cerebral artery • Posterior cerebral artery • Optic apparatus (optic nerve and chiasm) • Trigeminal nerve • Facial nerve • Vestibulo-cochlear nerve • Other 	Prompt entry if previous option (In contact with critical neuro-vascular structures?) has been ticked
Major axis (mm)	Free field	Required entry Note to data collector: In mm to 1 dp. Measure on axial T1/CT + GAD
Minor axis (mm)	Free field	Required entry Note to data collector: In mm to 1 dp. Perpendicular to the major axis on axial T1/CT + GAD
Cor/sag major axis	Free field	Require entry Note to data collector: In mm to 1 dp. Maximum height
Location	Dropdown list/Check box <ul style="list-style-type: none"> • Convexity 	Required entry. Allow one option only Note to data collector: as per ICOM classification (appendix 2)

	<ul style="list-style-type: none"> • Parasagittal • Parafalcine • Sphenoid wing • Anterior midline • Post fossa-midline • Post fossa-lateral & posterior • Tentorial • Intraventricular • Pineal region 	
Location subcategory	Dropdown list/Check box <ul style="list-style-type: none"> • Anterior • Posterior • Falco-tentorial • Lateral • Medial (including ACP) • Cribriform plate/olfactory groove • Planum • Tuberculum/diaphragma sellae • Clival • Petro-clival • Anterior foramen magnum • Petrous • Squamous occipital • Posterior foramen magnum • Supratentorial • Infratentorial 	Required entry. Allow one option only Note to data collector: ICOM classification (appendix 2) Appropriate subcategories will appear based on main category selected
Side	Dropdown list/check box <ul style="list-style-type: none"> • Right • Left • Midline 	Required entry. Allow one option only
MANAGEMENT DECISION (PAGE/SECTION 4)		
Decision	Dropdown list/Check box	Required entry. Allow one option only

	<ul style="list-style-type: none"> • Active monitoring • Surgery • SRS • fRT • Discharge from outpatient care • <u>Lost to follow-up</u> • <u>Dead</u> 	Note to data collector: You will be directed to the relevant page/section dependent on the choice. If the patient died or was lost to follow-up after this point in time, please choose one of the last two options, albeit the intention might have been to continue monitoring or intervene.
ACTIVE MONITORING (SECTION/PAGE 5)		
Scan date	DD/MM/YYYY	Required entry
Peritumoural signal intensity on T2	Dropdown list/check box <ul style="list-style-type: none"> • 0-5% • 6-33% • 34-66% • 67-100% • NA 	Required entry. Allow one option only Note to data collector: In relation to tumour volume on T2/FLAIR MRI. If only CT or T1 MRI available, NA
Peritumoural signal intensity on FLAIR	Dropdown list/check box <ul style="list-style-type: none"> • 0-5% • 6-33% • 34-66% • 67-100% • NA 	Required entry. Allow one option only Note to data collector: In relation to tumour volume on FLAIR MRI. If only CT or T1 MRI available, NA
Venous sinus nearby	Checkbox	Required entry. Note to data collector: Tick box if within 10 mm, in direct contact or invading one of: superior sagittal sinus (SSS), sigmoid sinus (SS), transverse sinus (TS), cavernous sinus (CS) and the confluence of sinuses (CoS)
If yes, specify	Dropdown list/check box <ul style="list-style-type: none"> • Superior sagittal sinus • Cavernous sinus • Sigmoid sinus • Transverse sinus • Confluence of sinuses 	Prompt entry if previous option (venous sinus nearby) has been ticked. Allow one option only
Separate, direct contact or invaded?	Dropdown list/check box <ul style="list-style-type: none"> • Separate • Direct contact • Invaded 	Prompt entry if previous option (venous sinus nearby) has been ticked. Allow one option only

Any new meningioma-related symptoms?	Checkbox	Required entry
If yes, specify domain	Dropdown list/check box <ul style="list-style-type: none"> • Seizure • Headache • Motor • Sensory • Language • Cognitive • Other 	Prompt entry if previous option (Any new meningioma-related symptoms?) has been ticked. Allow multiple options
Major axis (mm)	Free field	Required entry Note to data collector: In mm to 1 dp. Measure on axial T1/CT + GAD if available
Minor axis (mm)	Free field	Required entry Note to data collector: In mm to 1 dp. Perpendicular to the major axis on axial T1/CT + GAD if available
Cor/sag major axis (mm)	Free field	Required entry Note to data collector: In mm to 1 dp. Maximum height
Outcome	Dropdown list/check box <ul style="list-style-type: none"> • Resume follow-up (active monitoring) • Surgery • SRS • fRT • Discharge • <u>Lost to follow-up</u> • <u>Dead</u> 	Required entry. Allow one option only Note to data collector: You will be directed to the relevant page/section dependent on the choice. If the patient died or was lost to follow-up after this interval scan, please choose one of the last two options, albeit the intention might have been to continue monitoring or intervene. If the option you choose is set to take place in the future, choose the option, save the data entered and exit the form with no further information required.
SURGERY (SECTION/PAGE 6)		
Surgery date	DD/MM/YYYY	Required entry
Indication for intervention	Dropdown list/checkbox <ul style="list-style-type: none"> • Clinical-radiological • Clinical • Radiological • Patient preference 	Required entry. Allow one option only
Preoperative WHO PS	Dropdown list/checkbox <ul style="list-style-type: none"> • 0 • 1 	Required entry. Allow one option only

	<ul style="list-style-type: none"> • 2 • 3 • 4 	
Preoperative comorbidities	<p>Check box</p> <ul style="list-style-type: none"> • Hypertension - systolic > 140 or diastolic > 90 and patients on medical treatment • Previous myocardial infarction • Congestive heart failure • Peripheral vascular disease • Previous stroke/TIA - If hemiplegia present, do not check • Hemi/paraplegia • Diabetes which requires medical treatment • Diabetes with end-organ damage - if so, do not check diabetes that requires treatment • COPD/Asthma • Renal disease • Mild liver disease - Hep B/C or cirrhosis without portal hypertension • Moderate to severe liver disease - cirrhosis with portal hypertension, jaundice, ascites • Peptic ulcer disease • Cancer - excluding basal cell carcinoma • Metastatic cancer - if so, do not check cancer 	<p>Required entry. Allow multiple options.</p> <p>Note to data collector: Age and comorbidities will be used to calculate the age adjusted Charlson comorbidity index. Each of these is defined in the guide provided</p>

	<ul style="list-style-type: none"> • Rheumatic or connective tissue disease • HIV/AIDS • Skin ulcers/cellulitis • Depression • Dementia • On Warfarin 	
Simpson grade	Dropdown list/check box <ul style="list-style-type: none"> • 1-GTR • 2-GTR • 3-GTR • 4-STR • 5-STR 	Required entry. Allow one option only
WHO grade at the time of surgery	Dropdown list/check box <ul style="list-style-type: none"> • 1 • 2 • 3 	Required entry. Allow one option only Note to data collector: According to the WHO classification at the time of surgery
Microscopic brain invasion	Dropdown list/checkbox <ul style="list-style-type: none"> • Yes • No • Brain tissue absent • NA 	Required entry. Allow one option only Note to data collector: as described in the pathology report.
Updated WHO grade (2016)	Dropdown list/check box <ul style="list-style-type: none"> • 1 • 2 • 3 • NA 	Required entry. Allow one option only. Only to appear if date of surgery <2017 Note to data collector: For meningiomas operated prior to 2016, grading will have been done according to the 2007 classification. The 2016 version can upgrade WHO grade 1 meningiomas to grade 2 if microscopic brain invasion is present. This means that WHO grade 2 and 3 meningiomas remain unchanged. Grade 1 meningiomas on the other hand can be upgraded in the presence of brain invasion. This requires review by a pathologist and so if not feasible, choose NA. For meningiomas classed according to the 2016 WHO classification, grade remains unchanged.
Postoperative surgical complications	Checkbox	Required
Complication	Dropdown list/check box <ul style="list-style-type: none"> • Haemorrhage • Hydrocephalus 	Prompt entry if previous option (Postoperative surgical complications) has been ticked Allow more the one option

	<ul style="list-style-type: none"> • Surgical site infection - superficial and deep incision • Surgical site infection - intracranial (meningitis, ventriculitis and abscess) • Stroke • CSF leak • Other 	
New or worsening neurological impairment	Checkbox	Prompt entry if previous option (Postoperative surgical complications) has been ticked Note to data collector: If symptoms present tick box. Note that some patients will have a radiological haemorrhage on postoperative imaging with no symptoms. Include these but don't tick clinical manifestation. On the other hand, some patients will have new symptoms such as seizure with no radiological cause, include these as well.
Clinical manifestation	Dropdown list/checkbox <ul style="list-style-type: none"> • Seizure • Headache • Motor • Sensory • Language • Cognitive • Reduced GCS • Other 	Prompt entry if previous option (New or worsening neurological impairment) has been ticked. Allow multiple options
Pharmacological intervention	Checkbox	Prompt entry if previous option (Postoperative surgical complications) has been ticked
Surgical intervention	Dropdown list/checkbox <ul style="list-style-type: none"> • No • Without GA • Under GA 	Prompt entry if previous option (Postoperative surgical complications) has been ticked
ICU admission	Checkbox	Prompt entry if previous option (Postoperative surgical complications) has been ticked
Organ failure	Dropdown list/checkbox <ul style="list-style-type: none"> • None • Single-organ • Multi-organ 	Prompt entry if previous option (Postoperative surgical complications) has been ticked. Allow one option only
Persisted with no improvement beyond 30 days?	Checkbox	Prompt entry if previous option (Postoperative surgical complications) has been ticked

Postoperative medical complications	checkbox	Required
Complication	Dropdown list/check box <ul style="list-style-type: none"> • Myocardial infarction • Arrhythmia • Pneumonia • Pulmonary embolism • Deep venous thrombosis • Urinary tract infection • Acute kidney injury • Other 	Prompt entry if previous option (Postoperative medical complications) has been ticked Allow more than one option
Pharmacological intervention	Checkbox	Prompt entry if previous option (Postoperative medical complications) has been ticked
Surgical intervention	Dropdown list/checkbox <ul style="list-style-type: none"> • No • Without GA • Under GA 	Prompt entry if previous option (Postoperative medical complications) has been ticked
ICU admission	Checkbox	Prompt entry if previous option (Postoperative medical complications) has been ticked
Organ failure	Dropdown list/checkbox <ul style="list-style-type: none"> • None • Single-organ • Multi-organ 	Prompt entry if previous option (Postoperative medical complications) has been ticked. Allow one option only
Persisted with no improvement beyond 30 days?	Checkbox	Prompt entry if previous option (Postoperative medical complications) has been ticked
Postoperative WHO PS	Dropdown list/checkbox <ul style="list-style-type: none"> • 0 • 1 • 2 • 3 • 4 • 5 (dead) 	Required. Allow one option only
Recurrence	Checkbox	Prompt entry if previous option (Postoperative WHO PS) is not 5
Scan date (at recurrence or last follow-up date if no recurrence)	DD/MM/YYYY	Prompt entry if previous option (Postoperative WHO PS) is not 5
WHO PS at time of recurrence/last follow-up	Dropdown list/checkbox <ul style="list-style-type: none"> • 0 	Prompt entry if previous option (Postoperative WHO PS) is not 5

	<ul style="list-style-type: none"> • 1 • 2 • 3 • 4 	
SRS (SECTION/PAGE 7)		
Pre-radiation WHO PS	Dropdown list/check box <ul style="list-style-type: none"> • 0 • 1 • 2 • 3 • 4 	Required entry. Allow one option only
Pre-radiation comorbidity	Check box <ul style="list-style-type: none"> • Hypertension - systolic > 140 or diastolic > 90 and patients on medical treatment • Previous myocardial infarction • Congestive heart failure • Peripheral vascular disease • Previous stroke/TIA - If hemiplegia present, do not check • Hemi/paraplegia • Diabetes which requires medical treatment • Diabetes with end-organ damage - if so, do not check diabetes that requires treatment • COPD/Asthma • Renal disease • Mild liver disease - Hep B/C or cirrhosis without portal hypertension 	Required entry. Allow multiple options. Note to data collector: Age and comorbidities will be used to calculate the age adjusted Charlson comorbidity index. Each of these is defined in the guide provided

	<ul style="list-style-type: none"> Moderate to severe liver disease - cirrhosis with portal hypertension, jaundice, ascites Peptic ulcer disease Cancer - excluding basal cell carcinoma Metastatic cancer - if so, do not check cancer Rheumatic or connective tissue disease HIV/AIDS Skin ulcers/cellulitis Depression Dementia On Warfarin 	
Dose	Free field	Required entry
Early CTCAE toxicity (≤3 months)	Checkbox	Required entry
Toxicity	Free field	<p>Prompt entry if previous option (Early CTCAE toxicity (≤3 months)) is ticked</p> <p>Note to data collector: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm Use the following format: System class organ (SOC)-CTCAE term-grade e.g. nervous system disorders-headache-1. Select the complication with the highest toxicity grade</p>
Late CTCAE toxicity	Checkbox	Required entry
Toxicity	Free field	<p>Prompt entry if previous option (Late CTCAE toxicity) is ticked</p> <p>Note to data collector: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm Use the following format: System class organ (SOC)-CTCAE term-grade e.g. nervous system disorders-headache-1. Select the complication with the highest toxicity grade</p>
Meningioma progression/regrowth	Checkbox	Required
Scan date (at progression or last follow-up date if no progression)	DD/MM/YYYY	Required
WHO PS at time of progression/last follow-up	Dropdown list/checkbox <ul style="list-style-type: none"> 0 1 	Required. Allow one option only

	<ul style="list-style-type: none"> • 2 • 3 • 4 • 5 (dead) 	
fRT (SECTION/PAGE 8)		
Pre-radiation WHO PS	Dropdown list/check box <ul style="list-style-type: none"> • 0 • 1 • 2 • 3 • 4 	Required entry
Pre-radiation comorbidity	Check box <ul style="list-style-type: none"> • Myocardial infarction • Congestive heart failure • Peripheral vascular disease • Hemiplegia • Cerebrovascular disease • Pulmonary disease • Diabetes • Renal disease • Liver disease • Peptic ulcer disease • Cancer • Dementia • Connective tissue disease • AIDS • Hypertension • Skin ulcers/cellulitis • Depression • On Warfarin 	Required entry. Allow multiple options. Note to data collector: Age and comorbidities will be used to calculate the age adjusted Charlson comorbidity index. Each of these is defined in the guide provided
Number of fractions	Free field	Required entry
Fractionated dose	Free field	Required entry
Total dose	Free field	Required entry
Early CTCAE toxicity (≤3 months)	Checkbox	Required entry
Toxicity	Free field	Prompt entry if previous option (Early CTCAE toxicity (≤3 months)) is ticked

		Note to data collector: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm Use the following format: System class organ (SOC)-CTCAE term-grade e.g. nervous system disorders-headache-1. Select the complication with the highest toxicity grade
Late CTCAE toxicity	Checkbox	Required entry
Toxicity	Free field	Prompt entry if previous option (Late CTCAE toxicity) is ticked Note to data collector: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm Use the following format: System class organ (SOC)-CTCAE term-grade e.g. nervous system disorders-headache-1. Select the complication with the highest toxicity grade
Meningioma progression/regrowth	Checkbox	Required
Scan date (at progression or last follow-up date if no progression)	DD/MM/YYYY	Required
WHO PS at time of progression/last follow-up	Dropdown list/checkbox <ul style="list-style-type: none"> • 0 • 1 • 2 • 3 • 4 • 5 (dead) 	Required. Allow one option only
Discharge from outpatient care/Lost to follow-up (SECTION/PAGE 9)		
Date of data entry into the database	DD/MM/YYYY	Required entry
Rescanned during the time between discharge/loss to FU and the date of data entry	Checkbox	Required entry
Date of scan	DD/MM/YYYY	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked
Reason?	Dropdown list: <ul style="list-style-type: none"> • Seizure • Headache • Motor • Sensory • Language • Cognitive 	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked. Allow multiple options

	<ul style="list-style-type: none"> • Other 	
Peritumoural signal intensity on T2	Dropdown list/check box <ul style="list-style-type: none"> • 0-5% • 6-33% • 34-66% • 67-100% • NA 	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked. Allow one option only Note to data collector: In relation to tumour volume. If only baseline CT available, NA
Peritumoural signal intensity on FLAIR	Dropdown list: <ul style="list-style-type: none"> • 0-5% • 6-33% • 34-66% • 67-100% • NA 	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked. Allow one option only Note to data collector: In relation to tumour volume. If only baseline CT available, NA
Venous sinus nearby	Checkbox <ul style="list-style-type: none"> • Superior sagittal sinus • Cavernous sinus • Sigmoid sinus • Transverse sinus • Confluence of sinuses 	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked Note to data collector: Tick box if within 10 mm, in direct contact or invading one of: superior sagittal sinus (SSS), sigmoid sinus (SS), transverse sinus (TS), cavernous sinus (CS) and the confluence of sinuses (CoS)
If yes, specify	Dropdown list/check box	Prompt entry if previous option (venous sinus nearby) has been ticked. Allow one option only
Separate, direct contact or invaded?	Dropdown list/check box <ul style="list-style-type: none"> • Separate • Direct contact • Invaded 	Prompt entry if previous option (venous sinus nearby) has been ticked. Allow one option only
Major axis (mm)	Free field	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked Note to data collector: In mm to 1 dp. Measure on axial T1/CT + GAD
Minor axis (mm)	Free field	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked Note to data collector: In mm to 1 dp. Perpendicular to the major axis on axial T1/CT + GAD
Cor/sag major axis (mm)	Free field	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked Note to data collector: In mm to 1 dp. Maximum height
Verdict	Dropdown list/checkbox <ul style="list-style-type: none"> • Related 	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked. Allow one option only

	<ul style="list-style-type: none"> • Unrelated 	Note to data collector: Were the symptoms attributed to the meningioma?
Outcome	Dropdown list/Checkbox <ul style="list-style-type: none"> • Resume follow-up (active monitoring) • Surgery • SRS • fRT • Discharge • <u>Lost to follow-up</u> • <u>Dead</u> 	Prompt entry if previous option (Readmitted/rescanned during the time between discharge/loss to FU and the date of data entry) has been checked. Allow one option only Note to data collector: You will be directed to the relevant page/section dependent on the choice. If the patient died or was lost to follow-up after this interval scan, please choose one of the last two options, albeit the intention might have been to continue monitoring or intervene. If the option you choose is set to take place in the future, choose the option, save the data entered and exit the form with no further information required.
Overall outcome	Dropdown list/Checkbox: <ul style="list-style-type: none"> • Dead • Alive 	Prompt entry if previous option (Rescanned during the time between discharge/loss to FU and the date of data entry) is not ticked. Allow one option only
Mortality (SECTION/PAGE 10)		
Date of death	DD/MM/YYYY	Required entry
Cause of death	Dropdown list/checkbox <ul style="list-style-type: none"> • Meningioma-related • Unrelated 	Required entry. Allow one option only Note to data collector: An example of a meningioma-related death would be for example status epilepticus in a patient who manifested seizures but didn't have treatment. An unrelated death would be for example a community acquired pneumonia. For the purpose of the study, any death occurring from a morbidity, which did not necessitate neurosurgical input/opinion will be classified as unrelated

10.2. Appendix. 2. ICOM classification of meningioma location

ICOM classification system of meningioma locations			
Main category	Subcategories		
Convexity	Anterior ¹	Posterior ¹	
Parasagittal	Anterior ¹	Posterior ¹	Falco-tentorial
Parafalcine	Anterior ¹	Posterior ¹	Falco-tentorial
Sphenoid wing	Lateral	Medial (including ACP)	
Anterior midline	Cribriform plate or olfactory groove ²	Planum ³	Tuberculum and diaphragma sellae
Posterior fossa - midline	Clival	Petro-clival	Anterior foramen magnum ⁴
Posterior fossa – Lateral & posterior	Petrous	Squamous occipital	Posterior foramen magnum ⁴
Tentorial	Supratentorial	Infratentorial	
Intraventricular			
Pineal region⁵			

¹ The main attachment is located anterior or posterior, respectively, to the coronal suture

² Arising between the crista galli and the fronto-sphenoid suture

³ Arising between the fronto-sphenoid suture and the limbus sphenoidale

⁴ The main attachment is located anterior or posterior, respectively, to the hypoglossal canal

⁵ No obvious tentorial attachment